Fondazione Policlinico Universitario A. Gemelli, U.O.C. Oncologia Medica
Welcome,         Profile    Billing    Logout  
 2 Trials 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bria, Emilio
TEMPLE-2, NCT05785208: Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

Recruiting
4
122
Europe
Osimertinib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non Small Cell Lung Cancer
02/24
10/25
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Recruiting
3
670
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small-Cell Lung
03/26
03/28
MP-LALC, NCT03379441: Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

Not yet recruiting
2
126
Europe
Pembrolizumab Injectable Product
University of Turin, Italy
Non Small Cell Lung Cancer Patients
01/23
01/23
ALNEO, NCT05015010 / 2020-003432-25: Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Active, not recruiting
2
33
Europe
Alectinib
Gruppo Oncologico Italiano di Ricerca Clinica
Non Small Cell Lung Cancer
12/24
12/26
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Recruiting
2
142
Europe
Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide
Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
08/28
06/29
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
BDMO, NCT06367491: National Database of Bone Metastases

Recruiting
N/A
800
Europe
Registration in a database
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Bone Metastases
01/30
01/30
GALILEO, NCT06234579: Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

Recruiting
N/A
108
Europe
Biopsy (tissue or liquid), Alectinib, Brigatinib, Lorlatinib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ALK Gene Mutation, NSCLC Stage IV, ALK Sensitizing Mutation
03/26
07/26
Key-Early, NCT06467383: A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

Recruiting
N/A
600
Europe
MSD Italia S.r.l., YGHEA, CRO Division of Ecol Studio spa
Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I
06/25
06/25
EROS, NCT06532149: ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Recruiting
N/A
80
Europe
Alectinib, Alecensa, Brigatinib, ALUNBRIG, Lorlatinib 100 mg, LORVIQUA, Osimertinib, Sotorasib, Dabrafenib, Trametinib, Selpercatinib, Pembrolizumab, Cemiplimab, Nivolumab, Carboplatin, Pemetrexed, Paclitaxel
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NSCLC Stage IV, Sex Disorder, Hypogonadism, Male, Erectile Dysfunction
09/26
09/26
NCT06076005: Lung Cancer ID (Identity) Study

Recruiting
N/A
1000
Europe
Advanced lung cancer patients' group
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lung Cancer Stage IV
06/25
10/25
PICASSO, NCT05797493: Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer

Recruiting
N/A
100
Europe
Atezolizumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Small Cell Lung Cancer
06/27
06/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bria, Emilio
TEMPLE-2, NCT05785208: Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

Recruiting
4
122
Europe
Osimertinib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Non Small Cell Lung Cancer
02/24
10/25
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Recruiting
3
670
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small-Cell Lung
03/26
03/28
MP-LALC, NCT03379441: Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC

Not yet recruiting
2
126
Europe
Pembrolizumab Injectable Product
University of Turin, Italy
Non Small Cell Lung Cancer Patients
01/23
01/23
ALNEO, NCT05015010 / 2020-003432-25: Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Active, not recruiting
2
33
Europe
Alectinib
Gruppo Oncologico Italiano di Ricerca Clinica
Non Small Cell Lung Cancer
12/24
12/26
CARRY-ON, NCT06663098: Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Recruiting
2
142
Europe
Atezolizumab, humanized IgG1 monoclonal antibody against PD-L1, Carboplatin, re-challenge chemotherapy, Etoposide
Gruppo Oncologico Italiano di Ricerca Clinica, Roche Pharma AG
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
08/28
06/29
PREcoopERA, NCT05896566: A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer

Recruiting
2
220
Europe
Giredestrant, Triptorelin, Anastrozole
ETOP IBCSG Partners Foundation, Hoffmann-La Roche
Breast Cancer
06/26
06/26
BDMO, NCT06367491: National Database of Bone Metastases

Recruiting
N/A
800
Europe
Registration in a database
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Bone Metastases
01/30
01/30
GALILEO, NCT06234579: Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

Recruiting
N/A
108
Europe
Biopsy (tissue or liquid), Alectinib, Brigatinib, Lorlatinib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ALK Gene Mutation, NSCLC Stage IV, ALK Sensitizing Mutation
03/26
07/26
Key-Early, NCT06467383: A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

Recruiting
N/A
600
Europe
MSD Italia S.r.l., YGHEA, CRO Division of Ecol Studio spa
Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I
06/25
06/25
EROS, NCT06532149: ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Recruiting
N/A
80
Europe
Alectinib, Alecensa, Brigatinib, ALUNBRIG, Lorlatinib 100 mg, LORVIQUA, Osimertinib, Sotorasib, Dabrafenib, Trametinib, Selpercatinib, Pembrolizumab, Cemiplimab, Nivolumab, Carboplatin, Pemetrexed, Paclitaxel
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NSCLC Stage IV, Sex Disorder, Hypogonadism, Male, Erectile Dysfunction
09/26
09/26
NCT06076005: Lung Cancer ID (Identity) Study

Recruiting
N/A
1000
Europe
Advanced lung cancer patients' group
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lung Cancer Stage IV
06/25
10/25
PICASSO, NCT05797493: Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer

Recruiting
N/A
100
Europe
Atezolizumab
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Small Cell Lung Cancer
06/27
06/27

Download Options